2021•Hematological OncologyOpen access
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA IN THE REAL WORLD
Pavel Vodička, Kateřina Benešová, Andrea Janíková, Vít Procházka, David Belada, Heidi Móciková, Kateřina Steinerová, J Duras, Josef Karban, Veronika Hanáčková, A Sykorova, Aleš Obr, Marek Trněný
Open full text 6 citations
Abstract
Results: A total of 57 patients (41M:16F, median age at R-GDP rescue of 55 years [22-76]) were included: 36 diffuse large B-cell lymphoma (DLBCL), 11 other aggressive B-NHL and 10 follicular lymphoma; 10 DLBCL transformed from an indolent lymphoma.81% of patients received R-GDP as 2 nd line.Median time from diagnoses to R-GDP administration was 10 months (2-175) and most of the patients (56%) received 3 cycles.Grade 3-4 toxicity was observed in 42% of cases, mostly hematological (table).Hospital admission was required in 18% of cases with a median stay of 7 days.Main reason for admission was infectious complications (42% neutropenic fever) despite prophylactic G-CSF in 85% of cases.Response was: complete remission (CR) 18 (32%), partial remission 11 (19%), progression 28 (49%).Mobilization with G-CSF (10 µg/Kg/12h, median 5 days) was carried EA -previously submitted to regional or national meetings (up to 1000 attendees).
Open-access reader